Get the Stockscreener App
1.69
0.60%
0.01
Okyo Pharma Limited stock is traded at $1.69, with a volume of 78,073.
It is up +0.60% in the last 24 hours and up +13.42% over the past month.
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
See More
Previous Close:
$1.68
Open:
$1.7
24h Volume:
78,073
Relative Volume:
1.02
Market Cap:
$88.69M
Revenue:
-
Net Income/Loss:
$-4.61M
P/E Ratio:
-13.48
EPS:
-0.1254
Net Cash Flow:
$-3.10M
1W Performance:
+7.64%
1M Performance:
+13.42%
6M Performance:
-38.77%
1Y Performance:
-40.91%
1-Day Range:
$1.65
$1.7285
1-Week Range:
$1.57
$1.85
52-Week Range:
$1.42
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.69 | 88.69M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Piper Sandler | Overweight |
| Dec-08-25 | Initiated | B. Riley Securities | Buy |
Okyo Pharma Limited Stock (OKYO) Latest News
OKYO Forecast — Price Target — Prediction for 2027 - TradingView
OKYO Pharma advances toward Phase 3 FDA trialICYMI - Proactive financial news
OKYO's urcosimod gets FDA nod, moves to global phase 3 trial for NCP - Eyes On Eyecare
symbol__ Stock Quote Price and Forecast - CNN
OKYO Pharma secures positive FDA feedback for Urcosimod - grafa.com
Market movers: Alibaba, Broadcom, FuelCell Energy, OKYO Pharma... - Proactive financial news
OKYO Pharma clears key FDA milestone, advances toward Phase 3 trial for Neuropathic corneal pain - Proactive financial news
OKYO Pharma advances urcosimod to Phase 3 trial for neuropathic corneal pain after positive FDA feedback - Pluang
OKYO Pharma reports FDA feedback, advances urcosimod into Phase 3 trial for neuropathic corneal pain - Yahoo! Finance Canada
OKYO Pharma receives FDA feedback on phase 3 neuropathic pain trial - Investing.com
OKYO Pharma Secures FDA Backing to Advance Urcosimod into Global Phase 3 Trial for Neuropathic Corneal Pain - TipRanks
OKYO Pharma Receives 'Positive Feedback' From FDA Meeting About Phase 3 Trial of Urcosimod to Treat Neuropathic Corneal Pain - marketscreener.com
OKYO Pharma (NASDAQ: OKYO) gets FDA feedback on pivotal Phase 3 NCP trial - Stock Titan
FDA feedback pushes OKYO Pharma into Phase 3 eye-pain study - Stock Titan
OKYO Pharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium - TipRanks
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium - The Manila Times
OKYO Pharma (OKYO) to join Piper Sandler 2026 Virtual Ophthalmology Symposium fireside chat - Stock Titan
OKYO Pharma CEO to speak at Piper Sandler virtual eye event July 9 - Stock Titan
OKYO Pharma announces participation in Piper Sandler 2026 Virtual Ophthalmology Symposium - Proactive financial news
Price to book forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Price to earnings forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBITDA forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to revenue forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – NASDAQ:OKYO - TradingView
Enterprise value to EBIT forward of OKYO Pharma Limited – BOATS:OKYO - TradingView
OKYO Pharma Limited Actuals & Estimates (NASDAQ:OKYO) - TradingView
OKYO Pharma Ltd (OKYO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OKYO Pharma (OKYO) Edges Higher as Biotech Stock Tests Key Resistance Near $1.67Channel Breakout - dars.gov.et
OKYO Pharma And The Small-Cap Eye Care Story - Kalkine Media
OKYO Pharma Ltd (OKYO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO (NASDAQ: OKYO) CMO Mantelli reports multi-year option holdings in Form 3 - Stock Titan
OKYO Pharma (OKYO) director awarded options on 3,500 common shares - Stock Titan
OKYO Pharma (OKYO) director awarded options for 6,500 shares at $1.85 - Stock Titan
Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares - Stock Titan
OKYO Pharma (OKYO) CFO receives grant of 40,000 options at $1.85 - Stock Titan
OKYO Pharma (OKYO) director adds 300,000-share grant via Panetta Partners - Stock Titan
OKYO Pharma Slips 1.85% as Shares Test Key Support LevelTrend Following Picks - newsline.com
OKYO Pharma (OKYO) Retreats Toward Support as Biotech Sector Faces HeadwindsATR Stop - dars.gov.et
OKYO Pharma (OKYO) director reports detailed stock option grants - Stock Titan
OKYO H2'25 Earnings: EPS estimate is (0.08) USD - TradingView
OKYO Pharma (OKYO) director discloses stock and option holdings - Stock Titan
[Form 3] OKYO Pharma Ltd Initial Statement of Beneficial Ownership - Stock Titan
OKYO Pharma Edges Lower, Holds Steady Near Key Support LevelStop Loss Guidance - newsline.com
OKYO Stock Price, Quote & Chart | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
Okyo Pharma Limited Stock (OKYO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):